0001641404-24-000002.txt : 20241227 0001641404-24-000002.hdr.sgml : 20241227 20241227094521 ACCESSION NUMBER: 0001641404-24-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20241227 DATE AS OF CHANGE: 20241227 EFFECTIVENESS DATE: 20241227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Peca Labs, Inc. CENTRAL INDEX KEY: 0001641404 ORGANIZATION NAME: IRS NUMBER: 455481501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-533427 FILM NUMBER: 241582824 BUSINESS ADDRESS: STREET 1: 4424 PENN AVENUE, SUITE 201 CITY: PITTSBURGH STATE: PA ZIP: 15224 BUSINESS PHONE: 412-482-3755 MAIL ADDRESS: STREET 1: 4424 PENN AVENUE, SUITE 201 CITY: PITTSBURGH STATE: PA ZIP: 15224 D 1 primary_doc.xml X0708 D LIVE 0001641404 Peca Labs, Inc. 4424 PENN AVENUE, SUITE 201 PITTSBURGH PA PENNSYLVANIA 15224 412-482-3755 DELAWARE None None Corporation true C. Douglas Bernstein 4424 PENN AVENUE, SUITE # 201 PITTSBURGH PA PENNSYLVANIA 15224 Executive Officer Director CEO Dr. Joseph Bavaria 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Dr. Jeffrey Carpenter 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Barbara Carryer 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Brandon Haynes 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Jon Kuhn 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Michael Moriarty 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Samuel Navarro 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Jeff O?Donnell 4424 Penn Avenue, Suite #201 Pittsburgh PA PENNSYLVANIA 15224 Director Other Health Care Decline to Disclose 06b false 2024-12-12 false true true false 0 16500961 13925680 2575281 $6405085 of the Offering Amount & Amount Sold includes principal & accrued interest on convertible/exercisable into equity of Issuer. $95875 of the Offering Amount & Amount Sold includes expected gross proceeds assuming cash exercise of certain warrants. false 32 0 0 0 All proceeds will be used for product development, working capital, and satisfaction of other outstanding payment obligations of the Issuer. false Peca Labs, Inc. C. Douglas Bernstein C. Douglas Bernstein CEO 2024-12-27